Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis
- 9 January 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 35 (7) , 804-813
Abstract
Background: While the acute effects of cannabis are relatively benign for most users, some individuals experience significant adverse effects. This study aimed to identify whether variation in schizotypal personality traits and frequency of cannabis use influence the acute effects of delta-9-tetrahydrocannabinol (THC). Methods: Individual participant data from four double-blind, randomised, placebo-controlled, acute crossover studies involving 128 cannabis users were combined for a mega-analysis. Using multilevel linear models and moderation analyses, frequency of cannabis use and schizotypal personality traits were investigated as potential moderators of the subjective, cognitive and psychotomimetic effects of acute THC. Results: There was evidence of a moderating effect where increased frequency of cannabis use was associated with reduced intensity of subjective (changes in alertness and feeling stoned) and psychosis-like effects following THC when compared with placebo. Moderating effects of cannabis use frequency on acute memory impairment were weak. Trait schizotypy did not moderate the acute psychosis-like effects of THC compared with placebo. Conclusions: Our results suggest that a pattern of domain-specific tolerance develops to the acute effects of THC. Tolerance to the alertness-reducing effects occurred more readily than tolerance to psychotomimetic effects. Only partial tolerance to feeling stoned was found, and there was weak evidence for tolerance to memory impairment. Trait schizotypy did not moderate THC’s effects on psychotomimetic symptoms.Keywords
This publication has 61 references indexed in Scilit:
- Dose-Related Modulation of Event-Related Potentials to Novel and Target Stimuli by Intravenous Δ9-THC in HumansNeuropsychopharmacology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis usersPsychopharmacology, 2010
- Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosisPsychological Medicine, 2008
- Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic PerspectiveThe AAPS Journal, 2008
- Cannabis-Induced Psychotic-Like Experiences Are Predicted by High SchizotypyPsychopathology, 2008
- The Psychotomimetic States Inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabisSchizophrenia Research, 2008
- The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- An Experimental Study of Catechol-O-Methyltransferase Val158Met Moderation of Δ-9-Tetrahydrocannabinol-Induced Effects on Psychosis and CognitionNeuropsychopharmacology, 2006
- Patterns of cannabis use and positive and negative experiences of use amongst university studentsAddiction Research & Theory, 2006